A
Alnara Pharmaceuticals
Alnara Pharmaceuticals develops and commercializes orally-delivered protein therapeutics for the treatment of metabolic diseases
About Alnara Pharmaceuticals
Alnara Pharmaceuticals, Inc. is focused on creating novel protein therapeutics aimed at treating metabolic diseases. The company's unique approach involves designing protein therapies that can be administered orally and delivered directly to the gastrointestinal tract, bypassing the bloodstream. This method aims to enhance the effectiveness and safety of treatments for metabolic conditions. Based in Cambridge, Massachusetts, Alnara is supported by leading venture investors such as Frazier Healthcare Ventures, Third Rock Ventures, and Bessemer Venture Partners. The company primarily serves patients suffering from metabolic diseases, operating within the biopharmaceutical market. Alnara's business model revolves around the research, development, and commercialization of its proprietary protein therapies, generating revenue through product sales and potential partnerships. Keywords: protein therapeutics, metabolic diseases, oral delivery, gastrointestinal tract, biopharmaceutical, Cambridge, venture-backed, Frazier Healthcare, Third Rock Ventures, Bessemer Venture Partners.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2008
- Headquarters
- Cambridge, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 80.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Metabolism, Alternative Protein, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Alnara Pharmaceuticals.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2010 | $280M | — | Eli Lilly | — |
| SERIES BOther financing | Jan 2010 | $35M | $140M | MPM BioImpact | — |
Growth signals
Latest recorded traffic for Alnara Pharmaceuticals is 110 monthly website visits. Alnara Pharmaceuticals's team grew 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Longwood Fund
Series A4 investors entered at this stage
Third Rock Ventures
Frazier Healthcare Partners
Bessemer Venture Partners
MPM BioImpact
Other known investors1 additional known investor
Eli Lilly
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alnara Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alnara Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.